ArticleScientific reports2025
Introduction of Cistanche phelypaea fatty acids as a new natural neurotrophic supplement by evaluating its effects in normal and Alzheimer's diseased rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of the neurodegenerative disease "Alzheimer's"(AD) is expected to reach up to 2.1 billion people aged 60 years old by 2050. Unsaturated fatty acids have been implicated in both protective and detrimental roles in AD. However, there is currently limited understanding of how varying levels of disease pathology in the brain influence the abundance of these fatty acid species. Within this framework, the present study aims to estimate the effect of fatty acids extracted from Cistanche phelypaea (C. phelypaea) on rats' memory and behaviour. The fatty acids (FAs) extracted from the wild C. phelypaea were identified using GLC. Most of the FA were unsaturated. Oleic acid was the predominant fatty acid, followed by palmitic and linoleic acids. The study was conducted in two parallel arms, the first arm investigated the effect of C. phelypaea FAs on normal rats, and the second arm investigated its effect on Alzheimer's disease rats and involved the following groups of rats: normal & untreated AD groups, reference group: donepezil (0.75 mg/kg), & C. phelypaea groups (100 and 200 mg/kg), all treatments were given concomitantly with AlCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.